Sun Pharma takes Pfizer to court over Lyrica

India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica (pregabalin).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Pfizer and Sun settle Bosulif dispute

6 November 2019 Pfizer and Indian drugmaker Sun Pharmaceuticals have agreed to settle patent litigation over a generic version of Pfizer’s leukaemia drug, Bosulif.

Americas

Pfizer expects $1.9bn loss due to patent expirations

31 July 2018 US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.

Asia

Pfizer sues Sun Pharma for patent infringement

13 September 2016 Pfizer has sued Indian generic company Sun Pharma for allegedly infringing patents centring on Xeljanz, a treatment for rheumatoid arthritis.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Sun Pharma takes Pfizer to court over Lyrica

More on this story

Editor's picks

Editor's picks

More features